Mechanisms and

Arbeitsgruppe Dr. med. Bogner

Research Interests

Our laboratory is interested in the molecular processes that underlie tumorigenesis, tumor progression and tumor maintenance of malignant lymphoma.

Over the last decade, the incidence of indolent lymphoma is constantly increasing and the diseases remains incurable by conventional therapies. In contrast to aggressive lymphoma, the oncogenic events which drive the development of indolent lymphomas are little understood and remain elusive for most entities. However, prolonged cell survival ascribed to an imbalance of pro- and antiapoptotic proteins is a hallmark of most low-grade lymphomas, such as follicular lymphoma and chronic lymphocytic leukemia (CLL). 

The overexpression of the anti-apoptotic protein Bcl-2 is a common feature in both lymphomas and embedded in the translocation of chromosome 14;18. In addition, aberrant signalling through surface receptors, such as the B-cell receptor and CD40, cooperate with genetic alterations and sustain tumor cell survival. One focus of our work is to disentangle the aberrant signalling pathways which lead to the de-regulation and modulation of apoptosis proteins. We are currently investigating the integration of innate into adaptive immune responses in ZAP-70-positive chronic lymphocytic leukemia and the impact on induction of programmed cell death or survival.  Our work is dedicated not only to understand the pathogenesis of lymphomas, but also to help to invent new therapies for B-cell malignancies.

Another focus of our work is signalling pathways used in the communication between the tumor cell microenvironment and the malignant cell itself. It is tempting to speculate that the tumor cells themselves harness bystander cells to support their survival. Understanding how and when malignant B-cells and stromal cells interact will allow interference and offers a new approach to treat indolent lymphomas. In particular, we are interested how signalling through integrins is linked to defects in the apoptotic machinery. In addition, we investigate how the microenvironment is modulated by tumor cells and if interference with this modulation can be used as a new treatment strategy for lymphoma patients.


Written applications including CV are welcome and should be forwarded by e-mail to Dr. Christian Bogner.


Ihr Ansprechpartner


Dr. med.
Christian Bogner
Principal Investigator

Laboratory: Trogerstr. 32